Repare Therapeutics (NASDAQ:RPTX) Trading Down 4%
Repare Therapeutics (NASDAQ:RPTX) Trading Down 4%
Shares of Repare Therapeutics Inc. (NASDAQ:RPTX – Get Rating) fell 4% on Tuesday . The stock traded as low as $12.92 and last traded at $12.92. 987 shares traded hands during trading, a decline of 99% from the average session volume of 175,869 shares. The stock had previously closed at $13.46.
周二，雷帕雷治疗公司(Repare Treateutics Inc.)的股价下跌了4%。该股一度跌至12.92美元，最后报12.92美元。987股股票在交易中成交，较175,869股的平均成交量下降了99%。该股此前收盘价为13.46美元。
Analyst Ratings Changes
分析师评级发生变化
A number of equities research analysts recently issued reports on RPTX shares. HC Wainwright lowered their price objective on Repare Therapeutics from $38.00 to $25.00 and set a "buy" rating on the stock in a research note on Thursday, November 17th. Capital One Financial restated an "overweight" rating and set a $28.00 price target on shares of Repare Therapeutics in a research note on Friday. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $30.80.
一些股票研究分析师最近发布了关于RPTX股票的报告。11月17日，星期四，HC Wainwright在一份研究报告中将Repare治疗公司的目标价从38.00美元下调至25.00美元，并对该股设定了“买入”评级。Capital One Financial在周五的一份研究报告中重申了“增持”评级，并为Repare治疗公司的股票设定了28.00美元的目标价。一名研究分析师对该股的评级为持有，五名分析师对该公司股票的评级为买入。根据MarketBeat.com的数据，该公司目前的普遍评级为“适度买入”，平均目标价为30.80美元。
Repare Therapeutics Price Performance
修复治疗药物的价格表现
The business's 50-day moving average price is $15.50 and its 200 day moving average price is $13.94.
该业务的50日移动均线价格为15.50美元，200日移动均线价格为13.94美元。
Insider Buying and Selling
内幕买卖
In other Repare Therapeutics news, Director Davis Jerel sold 250,000 shares of the firm's stock in a transaction dated Friday, December 9th. The stock was sold at an average price of $16.00, for a total value of $4,000,000.00. Following the sale, the director now owns 2,094,451 shares of the company's stock, valued at approximately $33,511,216. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 30.30% of the stock is owned by company insiders.
在Repare Treateutics的其他新闻中，董事Davis Jerel在一笔日期为12月9日(星期五)的交易中出售了250,000股该公司股票。股票以16.00美元的平均价格出售，总价值为4,000,000.00美元。交易完成后，董事现在持有该公司2094,451股股票，价值约33,511,216美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的，该文件可通过此超链接。30.30%的股份由公司内部人士持有。
Institutional Trading of Repare Therapeutics
Repare治疗药物的制度性交易
Several institutional investors and hedge funds have recently made changes to their positions in the stock. Fred Alger Management LLC increased its stake in Repare Therapeutics by 6.8% in the third quarter. Fred Alger Management LLC now owns 24,311 shares of the company's stock valued at $295,000 after acquiring an additional 1,539 shares during the last quarter. State Street Corp raised its stake in shares of Repare Therapeutics by 1.2% during the third quarter. State Street Corp now owns 53,475 shares of the company's stock worth $649,000 after acquiring an additional 648 shares in the last quarter. Algert Global LLC purchased a new stake in shares of Repare Therapeutics in the 3rd quarter valued at $344,000. Trexquant Investment LP grew its holdings in shares of Repare Therapeutics by 55.5% during the 3rd quarter. Trexquant Investment LP now owns 79,674 shares of the company's stock valued at $966,000 after purchasing an additional 28,447 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in Repare Therapeutics by 0.8% in the 3rd quarter. Vanguard Group Inc. now owns 73,842 shares of the company's stock worth $895,000 after purchasing an additional 600 shares during the period. Hedge funds and other institutional investors own 78.19% of the company's stock.
几家机构投资者和对冲基金最近改变了他们在该股的头寸。弗雷德·阿尔杰管理有限责任公司第三季度将其在Repare Treateutics的持股增加了6.8%。弗雷德·阿尔杰管理有限责任公司在上个季度增持了1,539股股票后，现在拥有24,311股该公司股票，价值29.5万美元。道富集团在第三季度增持了Repare Treateutics的股份1.2%。道富银行目前持有53,475股该公司股票，价值649,000美元，此前该公司在上个季度又收购了648股。阿尔盖特全球有限责任公司在第三季度购买了Repare治疗公司的新股份，价值344,000美元。Trexquant Investment LP在第三季度增持了Repare Treeutics的股票55.5%。Trexquant Investment LP现在拥有79,674股该公司的股票，价值966,000美元，在上个季度又购买了28,447股。最后，先锋集团在第三季度将其在Repare治疗公司的地位提高了0.8%。先锋集团目前持有73,842股该公司股票，价值895,000美元，在此期间又购买了600股。对冲基金和其他机构投资者持有该公司78.19%的股份。
About Repare Therapeutics
关于Repare Treeutics
(Get Rating)
(获取评级)
Repare Therapeutics Inc, a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair.
Repare治疗公司是一家临床阶段的精确肿瘤学公司，通过在加拿大和美国使用其合成致命性方法来发现和开发治疗方法。该公司使用其SNIPRx，这是一个专有的、全基因组的和支持CRISPR的平台，以系统地发现和开发专注于基因组不稳定性(包括DNA损伤修复)的高度针对性的癌症疗法。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on Repare Therapeutics (RPTX)
- Can Lockheed Martin Corporation Hit Another All-Time High in Q1?
- Marathon Digital Holdings, Inc: Slow And Steady Wins The Race
- The WD-40 Company Is Ready To Rebound, But Will It?
- Skechers Not Nike Is The Sneaker Stock to Own for 2023
- Can The Rally In e.l.f. Beauty Stock Continue?
- 免费获取StockNews.com关于Repare治疗的研究报告(RPTX)
- 洛克希德·马丁公司第一季度能否再创历史新高？
- 马拉松数字控股公司：稳扎稳打赢得比赛
- WD-40公司已经准备好反弹了，但它会吗？
- 斯凯奇而不是耐克是2023年拥有的斯内克股票
- E.L.F.的拉力赛能否。美容股继续？
Receive News & Ratings for Repare Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repare Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受Repare治疗日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Repare Treeutics和相关公司的最新新闻和分析师评级的每日简要摘要。